Search

Displaying results 5131 - 5140 of 10000 in total
  1. Drug

    Regadenoson

    go.drugbank.com/drugs/DB06213
    ApprovedInvestigational

    Regadenoson is an A2A adenosine receptor agonist that causes coronary vasodilation and used for myocardial perfusion imagining. Manufactured by Astellas and FDA approved April 10, 2008.

  2. Drug

    Sitafloxacin

    go.drugbank.com/drugs/DB13261
    Investigational

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  3. Drug

    NCX 1015

    go.drugbank.com/drugs/DB05825
    Experimental

    NCX 1015 is nitric oxide-releasing derivative of prednisolone developed for the treatment of inflammatory bowel disease (IBD) by NicOx SA.

  4. Drug

    Phenindione

    go.drugbank.com/drugs/DB00498
    ApprovedInvestigational

    An indandione that has been used as an anticoagulant. Phenindione has actions similar to warfarin, but it is now rarely employed because of its higher incidence of severe adverse effects.

  5. Drug

    Mimopezil

    go.drugbank.com/drugs/DB05520
    Experimental

    Mimopezil is an acetylcholinesterase (AChE) inhibitor that has demonstrated potential use in the treatment of Alzheimer's disease. … Mimopezil is a pro-drug that is rapidly absorbed and converted into huperzine A.

  6. Drug

    Quinbolone

    go.drugbank.com/drugs/DB13484
    Experimental

    Categories: Anabolic Agents for Systemic Use
  7. Drug

    NAV 1800

    go.drugbank.com/drugs/DB05437
    Experimental

    RIGScan CR49, a 125I-labelled CR monoclonal antibody directed against the tumour-associated antigen TAG-72, is undergoing development with Neoprobe for the intraoperative detection of metastatic colorectal

  8. Drug

    Tarenflurbil

    go.drugbank.com/drugs/DB05289
    Investigational

    Tarenflurbil is an investigational drug that was studied in patients with mild Alzheimer's disease. … Aβ42 is the primary initiator of neurotoxicity and amyloid plaque development in the brains of Alzheimer's disease patients.

  9. Drug

    NS-3728

    go.drugbank.com/drugs/DB05835
    Experimental

    NS3728 is an orally active chloride channel blocker for the treatment of cancer.

  10. Drug

    LJP 1082

    go.drugbank.com/drugs/DB05446
    Experimental

    LJP 1082 is a Toleragen that is designed to shut down the B cells that produce antibodies to ß2 GP1. … The target of the LJP 1082's clot-promoting antibodies is a small region on a key blood protein called beta 2-glycoprotein I.